Navigation Links
Boosting vitamin D could slow progression, reduce severity of multiple sclerosis
Date:1/20/2014

Boston, MA For patients in the early stages of multiple sclerosis (MS), low levels of vitamin D were found to strongly predict disease severity and hasten its progression, according to a new study led by Harvard School of Public Health (HSPH) investigators in collaboration with Bayer HealthCare. The findings suggest that patients in the early stages of MS could stave off disease symptoms by increasing their vitamin D intake.

"Because low vitamin D levels are common and can be easily and safely increased by oral supplementation, these findings may contribute to better outcomes for many MS patients," said lead author Alberto Ascherio, professor of epidemiology and nutrition at HSPH.

The study will appear online January 20, 2014 in JAMA Neurology.

MS is a central nervous system disease that causes problems with muscle control and strength, vision, balance, feeling, and thinking. It's estimated by the World Health Organization that roughly 2.5 million people in the world have MS.

Previous research indicated a connection between low levels of vitamin D and risk of developing MS or having MS symptoms worsen, but those studies included patients with longstanding MS whose vitamin D levels could partly be a consequence, not a predictor, of disease severity. The new study looked at vitamin D levels among patients at the time of their first symptoms of the disease.

Researchers analyzed data from 465 MS patients from 18 European countries, Israel, and Canada who enrolled in 2002 and 2003 in the BENEFIT (Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) trial, which was aimed at comparing the effectiveness of early versus late interferon beta-1b in treating the disease. The scientists looked at how the patients' vitamin D levelswhich were measured at the onset of their symptoms and at regular intervals over a 24-month periodcorrelated with their disease symptoms and progression over a period of five years.

They found that early-stage MS patients who had adequate levels of vitamin D had a 57% lower rate of new brain lesions, a 57% lower relapse rate, and a 25% lower yearly increase in lesion volume than those with lower levels of vitamin D. Loss in brain volume, which is an important predictor of disability, was also lower among patients with adequate vitamin D levels. The results suggest that vitamin D has a strong protective effect on the disease process underlying MS, and underscore the importance of correcting vitamin D insufficiency, which is widespread in Europe and the U.S., the researchers said.

"The benefits of vitamin D appeared to be additive to those of interferon beta-1b, a drug that is very effective in reducing MS activity. The findings of our study indicate that identifying and correcting vitamin D insufficiency should become part of the standard of care for newly diagnosed MS patients," said Ascherio.


'/>"/>

Contact: Karen Feldscher
kfeldsch@hsph.harvard.edu
614-432-8439
Harvard School of Public Health
Source:Eurekalert

Related biology news :

1. New Brain Supplement Focus Boost Launches, Boosting Alertness, Memory and Focus
2. Immune-boosting colorectal cancer drug shows promise
3. Plant scientists at CSHL demonstrate new means of boosting maize yields
4. New American Chemical Society podcast: Boosting the sensitivity of airport security screening
5. Boosting galactan sugars could boost biofuel production
6. New health-economic model shows benefits of boosting dietary calcium intake
7. Boosting blood system protein complex protects against radiation toxicity
8. Vitamin D supplements reduce pain in fibromyalgia sufferers
9. Higher vitamin D levels associated with better cognition and mood in PD patients
10. Most clinical studies on vitamins flawed by poor methodology
11. HCG Injections and B12 shots now in stock at US Vitamin Injections Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has announced that the ... will take place on February 1-3, 2017 at the Roosevelt Hotel in New York ... program provides a unique 360-degree approach, which addresses the most up-to-date information regarding business ...
(Date:12/2/2016)... ... 01, 2016 , ... Orthogonal, a Chicago-based medical device software ... II 510(k) clearance for their flagship medical device, SimplECG. , With this FDA ... that rely on cloth-based nanosensors. While other companies have attempted to focus on ...
(Date:12/2/2016)... ... 2016 , ... Robots will storm the Prudential Center in Boston, MA during ... which is held on the United Nations International Day of Persons with Disabilities, will ... workplace. Suitable Technologies is partnering with NTI to showcase how technology can help individuals ...
(Date:12/2/2016)... , December 2, 2016 The immunohistochemistry ... growing at a CAGR of 7.3% during the forecast period of ... and diagnostic laboratories segment accounted for the largest share of immunohistochemistry ... ... on global immunohistochemistry (IHC) market spread across 225 pages, profiling 10 ...
Breaking Biology Technology: